News & Updates

Show Multimedia Only

Fixed-dose albendazole–ivermectin combo shows promise in T. trichiura, hookworm infections

21 Jan 2025

A single-pill combination that contains albendazole and ivermectin is superior to albendazole alone for treating Trichuris trichiura and hookworm infections, with similar safety profiles, according to data from a phase II/III trial.

Fixed-dose albendazole–ivermectin combo shows promise in T. trichiura, hookworm infections

21 Jan 2025

No increase in CV risk with JAKi vs TNFi for IBD

21 Jan 2025 by

Among patients with inflammatory bowel disease (IBD), treatment with Janus kinase inhibitors (JAKi) does not increase the risk of major adverse cardiovascular events (MACE) compared with tumour necrosis factor inhibitors (TNFi), according to a study presented at AIBD 2024.

No increase in CV risk with JAKi vs TNFi for IBD

21 Jan 2025

Which TKIs are safe, effective for EGFR-mutated NSCLC?

20 Jan 2025

First-line treatment with erlotinib, gefitinib, and osimertinib demonstrates safety and efficacy in patients with EGFR-mutated advanced nonsmall cell lung cancer (NSCLC), suggests a study.

Which TKIs are safe, effective for EGFR-mutated NSCLC?

20 Jan 2025

Increasing breast density elevates cancer risk

20 Jan 2025 by

Women with large breasts are at greater risk of developing breast cancer, reveals a study, indicating the important role of mammographic density as first measured in determining subsequent risk.

Increasing breast density elevates cancer risk

20 Jan 2025

Gallstone disease ups IBD risk

20 Jan 2025

People with gallstone disease are at higher risk of inflammatory bowel disease (IBD), regardless of other traditional risk factors, according to a study.

Gallstone disease ups IBD risk

20 Jan 2025

Risk-reducing surgeries tied to improved outcomes in BRCA carriers with young-onset BC

20 Jan 2025 by

A large global study provides evidence that risk-reducing mastectomy (RRM) and/or risk-reducing salpingo-oophorectomy (RRSO) is associated with improved survival outcomes in young women diagnosed with breast cancer (BC) at or before 40 years of age who were harbouring germline BRCA1 and/or BRCA2 pathogenic variants (PVs).

Risk-reducing surgeries tied to improved outcomes in BRCA carriers with young-onset BC

20 Jan 2025

Noncigarette tobacco products carry distinct health risks

20 Jan 2025

The use of noncigarette tobacco products is associated with distinctive cardiovascular outcomes, including stroke for cigar, heart failure for pipe, and total cardiovascular disease (CVD) for smokeless tobacco, as shown in a study.

Noncigarette tobacco products carry distinct health risks

20 Jan 2025

Novel drug for moderate-to-severe UC yields quality-of-life benefits

20 Jan 2025 by

RO7790121, an antibody against tumour necrosis factor-like ligand 1A (Anti-TL1A), helps improve the health-related quality of life (HR-QoL) for patients with moderately to severely active ulcerative colitis (UC), as shown in the phase IIb TUSCANY-2 trial.

Novel drug for moderate-to-severe UC yields quality-of-life benefits

20 Jan 2025

CTAD 2024: Origin of lecanemab and real-world experience in its use

20 Jan 2025 by

At the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference held in Madrid, Spain, researchers from the US and Japan shared real-world clinical experience with lecanemab, the first approved disease-modifying treatment for early Alzheimer’s disease (AD). Professor Lars Lannfelt of Uppsala University, Sweden, who received the CTAD Lifetime Achievement Award in recognition of his pioneering work that led to the development of the monoclonal antibody (mAb) drug, described the origins of his ground-breaking discovery.

CTAD 2024: Origin of lecanemab and real-world experience in its use

20 Jan 2025

T-DXd in HER2-low mBC: From molecular mechanism to clinical evidence and beyond

20 Jan 2025 by

HER2-low metastatic breast cancer (mBC) is a heterogeneous disease with diverse clinicopathological characteristics and limited later-line treatment options. During an industry-sponsored symposium organized by the Hong Kong Breast Oncology Group, Dr Erika Hamilton of Sarah Cannon Research Institute, Tennessee, US, discussed molecular mechanism and clinical evidence on the use of trastuzumab deruxtecan (T-DXd; Enhertu^®, Daiichi Sankyo & AstraZeneca) in pretreated HER2-low mBC.

T-DXd in HER2-low mBC: From molecular mechanism to clinical evidence and beyond

20 Jan 2025

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Fixed-dose albendazole–ivermectin combo shows promise in T. trichiura, hookworm infections

Fixed-dose albendazole–ivermectin combo shows promise in T. trichiura, hookworm infections

No increase in CV risk with JAKi vs TNFi for IBD

No increase in CV risk with JAKi vs TNFi for IBD

Which TKIs are safe, effective for EGFR-mutated NSCLC?

Which TKIs are safe, effective for EGFR-mutated NSCLC?

Increasing breast density elevates cancer risk

Increasing breast density elevates cancer risk

Gallstone disease ups IBD risk

Gallstone disease ups IBD risk

Risk-reducing surgeries tied to improved outcomes in BRCA carriers with young-onset BC

Risk-reducing surgeries tied to improved outcomes in BRCA carriers with young-onset BC

Noncigarette tobacco products carry distinct health risks

Noncigarette tobacco products carry distinct health risks

Novel drug for moderate-to-severe UC yields quality-of-life benefits

Novel drug for moderate-to-severe UC yields quality-of-life benefits

CTAD 2024: Origin of lecanemab and real-world experience in its use

CTAD 2024: Origin of lecanemab and real-world experience in its use

T-DXd in HER2-low mBC: From molecular mechanism to clinical evidence and beyond

T-DXd in HER2-low mBC: From molecular mechanism to clinical evidence and beyond